241 assets in Parkinson Disease

Therapeutic assets addressing Parkinson Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ent-01 Parkinson Disease	Enterin Inc.	P2	B (56)
Lenrispodun Parkinson Disease	Intra-Cellular Therapies, Inc.	P2	B (56)
Live Combined Bifidobacterium Parkinson Disease	Beijing Friendship Hospital	P4	B (56)
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules Parkinson Disease	Beijing Friendship Hospital	P4	B (56)
Sls-005 Trehalose Parkinson Disease	Neuromed IRCCS	P4	B (56)
aav2-gdnf Parkinson Disease	AskBio Inc	P2	CCC (55)
Bezisterim Parkinson Disease	BioVie Inc.	P2	CCC (55)
Izaflortaucipir Parkinson Disease	Michael J. Fox Foundation for Parkinson's Research	P2	CCC (55)
mt101-5 Parkinson Disease	Mthera Pharma Co., Ltd.	P2	CCC (55)
Prx-002 Parkinson Disease	Hoffmann-La Roche	P2	CCC (55)
Risvodetinib Parkinson Disease	ABLi Therapeutics, Inc.	P2	CCC (55)
ucb0022 Parkinson Disease	UCB Biopharma SRL	P2	CCC (55)
Biib122 Parkinson Disease	Denali Therapeutics Inc.	P3	CCC (54)
Dalzanemdor Parkinson Disease	Supernus Pharmaceuticals, Inc.	P2	CCC (54)
Lactobacillus Acidophilus Parkinson Disease	Tanta University	P3	CCC (54)
18f-mfbg Parkinson Disease	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	P2	CCC (53)
ab-1005 Parkinson Disease	Bayer	P2	CCC (53)
Bbm-P002 Parkinson Disease	Shanghai Xinzhi BioMed Co., Ltd.	P1	CCC (53)
Carvedilol Parkinson Disease	Cedars-Sinai Medical Center	P2	CCC (53)
Celecoxib Parkinson Disease	Tanta University	P2	CCC (53)
Ctc-413 Parkinson Disease	Chase Therapeutics Corporation	P2	CCC (53)
Hydroxychloroquine Parkinson Disease	Ottawa Hospital Research Institute	P2	CCC (53)
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-301 (88.7%) -(Ighd) -Ighj601 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg401, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-2902 (89.0%) -Igkj201(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) Parkinson Disease	TrueBinding, Inc.	P2	CCC (53)
N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE Parkinson Disease	Technical University of Munich	P2	CCC (53)
Sul-238 Parkinson Disease	GEN İlaç ve Sağlık Ürünleri A.Ş.	P2	CCC (53)
Alpha Tocopherol Parkinson Disease	Medipol University	P3	CCC (52)
Bia 28-6156 Parkinson Disease	Bial R&D Investments, S.A.	P2	CCC (52)
Furosemide Parkinson Disease	University of Alberta	P3	CCC (52)
gt-02287 Parkinson Disease	Gain Therapeutics, Inc.	P2	CCC (52)
Human Dopaminergic Progenitor Cells Parkinson Disease	iRegene Therapeutics Co., Ltd.	P2	CCC (52)
Hydrogen Parkinson Disease	dr. Siti Nurlaela, SpN	P2/3	CCC (52)
km-819 Parkinson Disease	FAScinate Therapeutics Inc.	P2	CCC (52)
Lu Af28996 Parkinson Disease	H. Lundbeck A/S	P2	CCC (52)
Oxyhydrogen Nanobubble Infusion Parkinson Disease	dr. Siti Nurlaela, SpN	P2/3	CCC (52)
Pittsburgh Compound B Unlabelled Parkinson Disease	Mayo Clinic	P2	CCC (52)
8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)- Parkinson Disease	GE Healthcare	P2	CCC (51)
Adipose-Derived Stromal Vascular Fraction Cells Parkinson Disease	Samuel Vilchez, PhD	P1/2	CCC (51)
Cilostazol Parkinson Disease	Ain Shams University	P2	CCC (51)
cpl500036 - high dose Parkinson Disease	Celon Pharma SA	P2	CCC (51)
cpl500036 - low dose Parkinson Disease	Celon Pharma SA	P2	CCC (51)
gm1 Parkinson Disease	Qilu Pharmaceutical Co., Ltd.	P2	CCC (51)
Pentoxifylline Parkinson Disease	Mostafa Bahaa	P2	CCC (51)
Remimazolam Parkinson Disease	VA Office of Research and Development	P2	CCC (51)
Suvecaltamide Parkinson Disease	Jazz Pharmaceuticals	P2	CCC (51)
Talineuren Parkinson Disease	InnoMedica Schweiz AG	P2	CCC (51)
Teonanacatl Parkinson Disease	Yale University	P2	CCC (51)
tj0113 Parkinson Disease	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (51)
tr-012001 Parkinson Disease	SNLD, Ltd.	P2	CCC (51)
Trans-Resveratrol Parkinson Disease	Georgetown University	P2	CCC (51)
Vutiglabridin Parkinson Disease	Glaceum	P2	CCC (51)

Showing 51 to 100 of 241 assets

PreviousPage 2 of 5Next